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Abstract: The primary structure of a new Kunitz-type protease inhibitor InhVJ from the 
sea anemone Heteractis crispa (Radianthus macrodactylus) was determined by protein 
sequencing and cDNA cloning. InhVJ amino acid sequence was shown to share high 
sequence identity (up to 98%) with the other known Kunitz-type sea anemones sequences. 
It was determined that the P1 Thr at the reactive site resulted in a decrease of the Ki of 
InhVJ to trypsin and α-chymotrypsin (7.38 × 10−8 M and 9.93 × 10−7 M, respectively). By 
structure modeling the functional importance of amino acids at the reactive site as well as 
at the weak contact site were determined. The significant role of Glu45 for the orientation 
and stabilization of the InhVJ-trypsin complex was elucidated. We can suggest that there 
has been an adaptive evolution of the P1 residue at the inhibitor reactive site providing 
specialization or functional diversification of the paralogs. The appearance of a key so-called 
P1 Thr residue instead of Lys might lead to refinement of inhibitor specificity in the direction 
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of subfamilies of serine proteases. The absence of Kv channel and TRPV1-receptor 
modulation activity was confirmed by electrophysiological screening tests. 
Keywords: sea anemone; Kunitz-type protease inhibitor; structure; function; channels 
 
1. Introduction 
Protein inhibitors regulate the activity of proteases involved in biochemical processes such as blood 
clotting, complement system, digestion, inflammation, apoptosis and others. In the case of protease 
inhibitor deficiency, some diseases may appear. Currently some attempts have been made in the 
therapeutic application of protease inhibitors [1–3]. Therefore, proteases and their inhibitors are 
attractive targets and intensively studied protein-protein complexes. Venomous animals are known to 
be a rich source of protease inhibitors, which can be used in biotechnology and medicine as prototypes 
for new generations of drugs.  
Besides neurotoxins, pore-forming toxins, and phospholipases A2, sea anemones also contain a 
large amount of protease inhibitors. To date about 40 low molecular mass protease inhibitors (6000 Da) 
from sea anemones have been isolated and partially characterized [4–23]. However, the complete 
amino acid sequences have only been determined for a few of them. The most known sea anemone 
inhibitors belong to the widely studied BPTI/Kunitz inhibitor family [24], except for Kasal-type 
inhibitors from Anemonia sulcata [13]. Their stable molecules consist of 56–60 amino acid residues, 
six of which are conservatively positioned cysteine residues forming three disulfide bonds.  
The Kunitz-type inhibitors interact with proteases by the classical substrate-like mechanism through 
a key P1 residue, which is located at the center of the canonical binding loop [25,26]. The majority of  
the sea anemone inhibitors have a positively charged Lys or Arg residue at the P1 position of the 
reactive site, which is known to be essential for inhibition of serine proteases, such as trypsin and  
α-chymotrypsin [11,17]. The inhibitor SHPI-1 from Stichodactyla helianthus has broad protease 
specificity and inhibits not only trypsin and chymotrypsin but also human neutrophil elastase (HNE), 
papain, and pepsin [11,27]. Some of the inhibitors from sea anemones are bifunctional molecules. 
They possess Kunitz-type protease as well as Kv1 channel inhibiting properties (type 2 toxins: 
AsKC1-AsKC3 or kalicludines 1–3 [17], SHTX III [20], and APEKTx1 [28]) or antihistamine activity 
(RmInI and RmInII [18]). 
It is worth mentioning that the sea anemone Heteractis crispa (Radianthus macrodactylus) 
produces, besides P1 Lys/Arg inhibitors, atypical polypeptides with the Thr residue at P1 position of its 
reactive site. Jn-IV is shown to be an inhibitor of trypsin [15], and polypeptides APHC1-APHC3 
weakly block the serine protease activity, but they modulate the activity of the TRPV1-receptor, 
causing the analgesic effect in experiments in vivo [21,22]. It has been well established that they also 
possess an anti-inflammatory activity [29]. Recently it has been deduced that the H. crispa 
polypeptides are encoded by a multigene superfamily and produced via a combinatory Kunitz-type 
library in the sea anemone venom [30]. According to the nature of a P1 residue of the 33 deduced 
mature polypeptides, three groups with Lys, Thr, and Arg have been categorized. It also has been 
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suggested there has been an adaptive evolution of the P1 residue at the inhibitor reactive site providing 
specialization or functional diversification of the paralogs.  
In this paper we report the determination of the primary structure and structure-function features of 
a new inhibitor InhVJ from the sea anemone H. crispa. To elucidate the specificity of the InhVJ, an 
extensive screening on ion channels was also performed. Furthermore, the structures of serine protease 
complexes were also analyzed. 
2. Results and Discussion 
2.1. Purification and Primary Structure Determination of InhVJ 
The protease inhibitor InhVJ was isolated from 70%-ethanol extract of H. crispa (R. macrodactylus) by 
the scheme, which was proposed to separate inhibitors from polypeptides, such as neurotoxins, 
actinoporins, and phospholipases A2. This scheme was described previously [19]. In brief, it includes a 
hydrophobic chromatography on Polychrome-1, gel filtration chromatography on Bio-gel P-4 and  
ion-exchange chromatography on SP-Sephadex G-25. The obtained fractions were further purified by 
RP-HPLC on Nucleosil C18 column (Figure 1a).  
As a result of the second purification by RP-HPLC under the same conditions, the individual 
polypeptide was obtained and named InhVJ (Figure 1b). Its amino acid composition was characterized by 
the presence of six cysteine residues and the absence of tryptophan and methionine [19]. According to 
MALDI-TOF/MS data, the InhVJ molecular mass was 6106 Da. InhVJ showed both trypsin  
(Ki = 7.38 × 10−8 M) and α-chymotrypsin (Ki = 9.93 × 10−7 M) inhibiting activity [31]. 
Figure 1. Purification of InhVJ, the result of alkylated inhibitor trypsin digestion and 
amino acid sequence of InhVJ. (a) RP-HPLC of fraction obtained after ion-exchange 
chromatography [19] on Nucleosil C18 (4.6 × 250 mm) column with a linear gradient of 
acetonitrile concentration; (b) Second purification of InhVJ by RP-HPLC under the same 
conditions described in A; the molecular mass of InhVJ determined by MALDI-TOF/MS 
(left inset of B); (c) RP-HPLC of peptides obtained after digestion of alkylated InhVJ by 
trypsin on Nucleosil C18 (4.6 × 250 mm) column with a linear gradient of acetonitrile 
concentration; (d) Amino acid sequence of InhVJ determined by Edman degradation. 
 
(a) 
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Figure 1. Cont. 
 
(b) 
 
(c) 
1 GSICLEPKVVGPCTAYFPRFYFDSETGKCTPFIYGGCEGNGNNFETLHACRAICRA 56
(d) 
To determine a complete amino acid sequence, alkylation of InhVJ and its further digestion by 
trypsin were carried out. The resulting five peptides obtained after the digestion were separated and 
desalted by RP-HPLC (Figure 1c). In Table 1, the molecular masses of each peptide determined by 
MALDI-TOF/MS and the amino acid sequences determined by Edman degradation are shown. 
Table 1. Amino acid sequences and molecular masses of tryptic peptides P1–P5. 
Peptide Amino acid sequence 
Molecular mass (MALDI)
Dа 
Molecular mass (theoretical) 
Da 
P-1 
P-2 
P-3 
P-4 
P-5 
GSICLEPK 
VVGPCTAYFPR 
FYFDSETGK 
AICRA 
CTPFIYGGCEGNGNNFETLHACR 
951.31 
1314.91 
1094.54 
637.73 
2818.95 
951.01 
1314.42 
1093.15 
637.66 
2818.75 
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On the basis of a tryptic peptide sequence comparison with the known sequence of the native 
inhibitor Jn-IV from H. crispa [15], the complete amino acid sequence of InhVJ (Figure 1d) was 
deduced. InhVJ consists of 56 amino acid residues and has a molecular mass according to the sequence 
analysis equal to 6112 Da. Since the molecular mass determined by MALDI-TOF/MS is 6106 Da, the 
difference of six mass units indicates that all six cysteine residues are involved in three disulfide bonds.  
The full-length cDNA encoding InhVJ was successfully obtained by combination of 3′ and 5′RACE 
techniques. It should be noted that the transcript corresponding to the full-length InhVJ was one of the 
most abundant transcripts (13.5%). The full-length cDNA includes 427 bp with an open reading frame 
of 234 bp, which encodes a polypeptide of 78 amino acid residues. The signal peptide is composed of 
22 amino acid residues. The mature polypeptide (56 aa) is identical to the sequence obtained by Edman 
degradation (Figure 2).  
Figure 2. Nucleotide sequence of full-length cDNA encoding InhVJ. The signal sequence 
is underlined, the amino acid sequence of InhVJ is shown by bold types, the stop-codon is 
marked by asterisks. 
 
2.2. Amino Acid Sequences and Phylogenetic Analysis  
A sequence similarity search in the GenBank database by the BLASTP program [32] revealed that 
the mature polypeptide InhVJ belongs to the Kunitz-type protease family. When aligned with the 
primary structures of known inhibitors (Figure 3), InhVJ shares the highest degree of homology—from 
91 to 96% of identity—with the trypsin inhibitor Jn-IV and with analgesic polypeptides APHC1-APHC3 
from H. crispa. It also shares a high degree of homology with HCGS-polypeptides recently deduced by 
the PCR-based cloning technique [30]. 
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Figure 3. Alignment of amino acid sequences of protease inhibitors, analgesic polypeptides, 
Kv channels toxins from sea anemones, and protease inhibitor from bovine pancreas. 
InhVJ, Jn-IV, APHC1-APHC3, HCGS 2.3, 1.34, 1.26, 1.10, 1.36 from H. crispa [15,21,22,30]; 
SHPI-1, SHPI-2 from S. helianthus [11,12]; SA5 II, AsKC1-AsKC3 from A. sulcata [16,17]; 
SHTX III from Stichodactyla haddoni [20]; APEKTx1 from Anthopleura elegantissima [28]; 
AXPI-I, AXPI-II, and AXPI-III from Anthopleura aff. xanthogrammica [9,10]; AEAPI, 
AEPI-I, and AEPI-II from Actinia equina [14,23]; AFAPI-I, AFAPI-III from Anthopleura 
fuscoviridis [23]; BPTI from Bos taurus [33]. Р1—amino acid residue of the inhibitor’s 
reactive center. The asterisks below the sequence of BPTI indicate the contact sites with 
serine proteases. Identical and conservative residues are indicated by dark and light gray colors. 
 
The sequence identity of InhVJ and inhibitors from other sea anemone species ranges from  
46% to 87%. It is worth mentioning that protease inhibitors from sea anemones belonging to the same 
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family have a higher degree of homology than the inhibitors from sea anemones belonging to different 
families. The percentage of identity of inhibitors from H. crispa (InhVJ), S. haddoni (SHTX III),  
and from S. helianthus (SHPI-1, SHPI-2) of the family Stichodactylidae is 50, 85 and 87%, 
respectively, whereas the percentage of identity of inhibitors from A. elegantissima (APEKTx1),  
A. aff. xanthogrammica (AXPI-I, AXPI-II, AXPI-III), A. sulcata (SA5 II, AsKC1-AsKC3), A. equina 
(AEAPI, AEPI-I, AEPI-II), and from A. fuscoviridis (AFAPI-I, AFAPI-III) of the family Actiniidae is 
in the range of 44%–61%. Besides, InhVJ shares a high degree of homology (up to 50%) with the 
polypeptides AsKC1-AsKC3, APEKTx1, and SHTX III, which also modulate voltage-gated potassium 
channel activity. Apparently, even though all these polypeptides evolved from a common ancestor and 
their structural Kunitz-fold has undergone hardly any significant changes during evolution, changes in 
variable parts of the molecules have taken place. These changes have not affected the overall fold of 
the polypeptide chain, but have led to the appearance of new functions such as Kv-channel inhibiting 
activity (type 2 toxins) or TRPV1-receptor modulating activity. 
Recently it was deduced that the H. crispa polypeptides are encoded by a multigene superfamily 
and produced via a combinatory Kunitz-type library in the sea anemone venom [30]. Combinatorial 
libraries of polypeptides have also been found in other poisonous organisms, such as cone snails [34], 
spiders [35], and scorpions [36]. The 33 deduced mature GS-polypeptides were divided into three groups 
according to the P1 amino acid residue at the reactive site: group I—with Lys, group II—with Thr, 
group III—with Arg. So, InhVJ with the Thr residue at the reactive site belongs to structural group II.  
Figure 4. Evolutionary relationships of the known sea anemone Kunitz-type protease 
inhibitors. The NJ phylogenetic tree was made using the Poisson correction with bootstrap 
test of 1000 replications in MEGA 4 [37]. Nodes with confidence values greater than 50% 
are indicated. 
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The phylogenetic analysis was performed to determine evolutionary relationships of sea anemone 
serine protease inhibitors. According to the NJ phylogenetic tree, InhVJ as well as Jn-IV, APHC1-APHC3, 
SHPI-1, and SHPI-2 protease inhibitors of the Stichodactylidae family belong to one cluster, except for 
inhibitor SHTX III. However, one can see that here is an additional dividing of H. crispa polypeptides 
into two subsets in this cluster, InhVJ-like and APHC1-APHC3-like subsets (Figure 4). Previously we 
have shown that the additional dividing of these polypeptides is also confirmed by the surface 
electrostatic potential distribution [30]. The InhVJ-like subset includes molecules with neutral or 
slightly positive total charges ranging from +0.02 to +1.03, while the APHC1-APHC3-like subset 
contains molecules with more positive charges ranging from +1.81 to +2.15. We can suggest that there 
has been an adaptive evolution of the P1 residue at the inhibitor reactive site providing specialization 
or functional diversification of the paralogs. On the one hand, the appearance of the Thr P1 residue 
instead of Lys might lead to refinement of inhibitor specificity in the direction of subfamilies of serine 
proteases. On the other hand, it also might lead to the appearance of polypeptides with, for instance, a 
new function such as TRPV1 modulation. 
2.3. Electrophysiological Experiments 
Type 2 toxins from sea anemones are known to be potent inhibitors of voltage-gated potassium 
channels. Kalicludines block Kv1.2 channels with an IC50 value of about 1 µM [17], SHTX III inhibits 
the binding of known potassium channel ligands, like 125I-α-DTX with a Kd value of 650 nM [20], and 
APEKTx1 blocks Kv1.1 channels with an IC50 value of 0.9 nM [28]. Despite the high sequence 
identity of InhVJ with these polypeptides (up to 50%) and our previous suggestion, based on the 
molecular modeling results that show that InhVJ might also inhibit KV channels, electrophysiological 
screening tests on several KV channel isoforms (together with the cardiac hERG channel) revealed that 
InhVJ in a concentration range of up to 50 µM had no modulatory activity (Figure 5a). Kv channel 
expressing oocytes were, without pre-incubation, exposed to 50 µM InhVJ for a period of time ranging 
from 5 to 10 min. All experiments were performed on at least three different oocytes (n ≥ 3). No 
significant alteration of the potassium currents was observed (p < 0.05). It has been proposed that 
heavily charged polypeptides adapt more easily to the negative electrostatic potential of the extracellular 
part of the potassium channels [38]. Since the total charge of InhVJ is only slightly positive +0.02, it 
apparently is not enough to inhibit KV channels. But perhaps more importantly, there is also no 
functional dyad consisting of basic and hydrophobic (aromatic) amino acids in the structure of InhVJ. 
They were hypothesized as key residues for such activity in APEKTx1 [28].  
As for InhVJ’s ability of blocking TRPV1-receptor activity, electrophysiological analysis revealed 
no activity of InhVJ in a concentration of up to 10 µM (Figure 5b). Oocytes expressing TRPV1 
channels were, without pre-incubation, exposed to 10 µM of InhVJ in the presence of 2 µM capsaicine 
for time intervals ranging from 10 to 60 s. No significant effect was observed (p < 0.03). APHC1 was 
shown to modulate TRPV1-receptor with an EC50 value of about 54 nM and inhibit capsaicin-induced 
currents (32% ± 9%) [21]. InhVJ and APHC1-APHC3 shared 91% to 96% sequence identity. The 
main difference between the polypeptide sequences was the substitution of His48Arg, which is 
important for TRPV1 modulation activity [21,31,39]. So the experimental data is in complete 
agreement with the results of phylogenetic analysis, where dividing of a cluster into two subsets of 
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InhVJ-like and analgesic polypeptides occurs. These results also confirm our suggestion that there is a 
functional specialization of InhVJ to only protease inhibition during evolution. 
Figure 5. (a) Activity profile of InhVJ on several KV channel isoforms and the cardiac 
hERG channel. The figure shows the results of one representative experiment. Whole-cell 
current traces in control and inhibitor conditions are shown. The dotted line indicates the 
zero-current level. The asterisk (*) marks steady-state current traces after application of  
50 µM inhibitor. No differences in currents were observed between control and toxin 
situation. (b) Activity profile of InhVJ on TRPV1-receptor. No activity after application of 
10 µM InhVJ was observed. CAP = capsaicine (2 μM); CZP = capsazepine (10 μM). All 
data represent the average of at least three independent experiments (n ≥ 3) and are 
presented as mean ± standard error.  
 
2.4. Comparison of Inhibitor Protease Inhibiting Activity 
The best-studied polypeptide of the Kunitz family BPTI is a potent inhibitor of serine proteases  
(Ki in the range 1011–1014 M). BPTI Lys14 (the numbering is based on the sequence of InhVJ) P1 
amino acid residue located at the center of the canonical binding loop plays an important role in the 
formation of stable complexes with proteases. The side chain of Lys14 penetrates deeply into the 
active site of trypsin and forms electrostatic interactions with its Asp189. It has been shown that the 
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replacement of BPTI Lys14 by point mutations into other amino acid residues leads to an increase of 
association constant in complexes with trypsin-like proteases. It was deduced that P1 aromatic  
(Trp, Phe), large hydrophobic (Met, Leu) and polar (Gln, Asn, Ser, His) amino acid residues form 
stronger complexes with trypsin and chymotrypsin than small (Gly, Ala), branched (Thr, Val, Ile) and 
acidic side-chains (Asp, Glu) do [40].  
Similar to BPTI, there are functionally important P1 Lys or Arg residues at reactive sites of the sea 
anemone inhibitors (Figure 3). Indeed, the polypeptides of the sea anemones H. crispa, A. sulcata, 
Rhodactis rhodostoma, S. helianthus, and A. elegantissima, like BPTI, are active towards trypsin (Table 2). 
Table 2. The inhibition constants of protease inhibitors from sea anemones. 
Sea anemone Inhibitor 
Кi (М) 
Trypsin α-chymotrypsin 
H. crispa 
InhVJ 7.38 × 10−8 [31] 9.93 × 10−7 [31] 
Jn-IV 9.6 × 10−9 [15] n.d. 
АРНС1 1.0 × 10−6 [21] 5.0 × 10−6 [21] 
АРНС2 0.9 × 10−6 [22] 4.5 × 10−6 [22] 
АРНС3 5.0 × 10−7 [22] 7.0 × 10−6 [22] 
A. sulcata 
SA5 II 3.0 × 10−10 [5] n.d. 
AsKC1-AsKC3 30 × 10−9 [17] n.d. 
R. rhodostoma - 9.5 × 10−10 [6] 3.3 × 10−8 [6] 
A. elegantissima APEKTx1 124 × 10−9 [28] n.d. 
S. helianthus SHPI-1 1.1 × 10−10 [11] 2.3 × 10−9 [11] 
B. taurus BPTI 6.0 × 10−14 [41] 1.8 × 10−13 [42] 
n.d.—not determined. 
It is worth mentioning that in the InhVJ, Jn-IV, and APHC1-APHC3 polypeptide structures from  
H. crispa, instead of Lys/Arg at position P1, there is a Thr residue previously not encountered in the 
Kunitz-type inhibitors reactive site. InhVJ was shown to be a specific inhibitor of two serine proteases, 
namely trypsin and α-chymotrypsin, and it had no activity on plasmin, thrombin, kallilrein, cysteine 
protease—papain, and aspartic protease—pepsin [31]. As the interaction between inhibitors with 
branched amino acid residues at the reactive site with trypsin-like proteases is known to be 
disadvantageous [40,43], an affinity of InhVJ, Jn-IV, and APHC1-APHC3 to trypsin, as opposed to 
BPTI and other sea anemone inhibitors, proved predictably lower (Ki 10−6–10−9 M) (Table 2). 
However, the constant value of InhVJ association with trypsin [31] was about two orders of magnitude 
higher, 1.36 × 107 M−1, than the same constant of a mutant form of the BPTI with the replacement 
Lys14Thr at the reactive site, 2.9 × 105 М−1 [40]. The contribution to the energy value of InhVJ 
association with trypsin is probably made both by amino acid residues at positions 10–17 located at the 
reactive site of the inhibitor and by the amino acid residues at positions 33–38 located at the weak 
contact site [44]. The constant values of InhVJ and mutant BPTI Lys14Thr association complexes with 
α-chymotrypsin appeared to be of the same order and were 1.01 × 106 M−1 and 2.9 × 106 M−1, respectively.  
Serine proteases (trypsin and elastase) are known to be involved in many inflammatory  
processes [45,46]. The elastase active site, as opposed to that of trypsin and α-chymotrypsin sites,  
is much smaller and better adapted to interact with branched (Thr, Val, Ile) amino acid residues at the 
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P1 position [43,44]. Inhibitors selectively inhibiting serine protease action can potentially be used in 
the therapy with or the design of new anti-inflammatory medicines. According to the in silico 
investigation, Jn-IV with Thr at P1 position was hypothesized to inhibit human neutrophil elastase 
HNE [29]. Apparently InhVJ can also possess this activity. However, this hypothesis requires further 
experimental confirmation. 
To elucidate the functional importance of amino acid residues in the complexes of InhVJ with 
serine proteases we used structural modeling methods. 
2.5. Structure Modeling 
Currently, there is a unique spatial structure of the protease inhibitor from the sea anemone  
S. helianthus SHPI-1 (PDB 1SHP) established by 1H-NMR spectroscopy [47]. The high percentage of 
identity (87%) of InhVJ with SHPI-1 allowed us to use this inhibitor structure as a template. A 
structural model of InhVJ was generated using the server SWISS-MODEL [48–50] (Figure 6). After 
energy minimization using the MOE software with the capacity of the OPLS-AA [51], the energy of 
the molecule was −1987 kJ/mol. 
Figure 6. The structural model of InhVJ. The structure is shown as a ribbon diagram, 
where α-helixes are indicated by red color, β-strands by yellow, β-bends by dark blue, and 
disordered structure by blue colors. The positions of disulfide bonds in the structure of the 
inhibitor are indicated as dots of grey and yellow colors. 
 
To analyze the quality of the generated model, the RMSD parameter of the 55 Cα atoms InhVJ to 
those of SHPI-1 backbone traces was calculated (0.14 Å). The Ramachandran plots of φ, ψ angles [52] 
show that almost 75% of the non-glycine residues fall within the most favorable regions of the plot 
(data not shown). Remaining residues lie within the additional favorable regions as defined by 
PROCHECK [53]. 
The content of secondary structure elements in the InhVJ structural model was determined by 
Molmol [54]. The 3D-model shares a Kunitz scaffold as expected according to its high sequence 
identity with the template. The InhVJ structure like BPTI and SHPI-1 structures contains two α-helices, 
located at the N- and C-termini of the molecule, two antiparallel β-strands and two large loops 
N 
C 
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(disordered structure) and is stabilized by three conservative disulfide bonds. Thus, the InhVJ 
structural model was accurate enough for further structural and functional studies. 
To highlight the mechanism of InhVJ interaction with serine proteases by the method of molecular 
docking, a structural model of InhVJ-trypsin complex was designed (Figure 7a). According to the 
obtained data, the interaction of InhVJ with both trypsin and α-chymotrypsin (data is not shown) had a 
canonical character which is typical for the Kunitz-type polypeptides [55]. Docking analysis showed 
that InhVJ had a single binding site with the trypsin active site area, substantially overlapping with the 
SHPI-1 binding site (PDBID 3M7Q) [56]. Notably, superimposition of the structures of InhVJ and 
SHPI-1 complexes with trypsin also revealed that despite keeping the position of the InhVJ binding 
site with trypsin, there was a slight deviation of the InhVJ molecule with RMSD 3.2 Å. 
Figure 7. (a) Superimposition of the theoretical model of complex InhVJ-trypsin and 
crystal structure of complex SHPI-1-trypsin (PDB ID 3M7Q). Structures are shown as the 
ribbon diagrams. The key residues of the enzyme active site are shown as bowls.  
(b) Intermolecular hydrogen bonds in InhVJ-trypsin complex and interacting amino acid 
residues are shown as sticks for InhVJ in cyan and for trypsin in light gray colors. 
(a) (b) 
Analysis of the polypeptide chain interactions in complex performed with MOE software shows 
that the complex formation is governed by van der Waals, hydrophobic and electrostatic forces as well 
as H-bonding (Figure 7b) (Supplementary data). One can see that the stabilizing H-bond number 
decreases in the complexes BPTI-trypsin > BPTI Lys14Thr-trypsin > InhVJ-trypsin > SHPI-1-trypsin. 
It is worth mentioning that the H-bond number formed by the P1 residue of inhibitors with the trypsin 
active site residues decreases from seven for BPTI Lys14 to five for SHPI-1 Lys14 and to three for 
InhVJ Thr14. These findings correlate well with the decreasing Ki values of their complexes (Table 2). 
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Besides, the complex interface analysis and the contribution of amino acid residues, localized at the 
reactive site (five amino acids) as well as at the weak contact site (three amino acids) to free binding 
energies for the complexes formation, were performed. According to computational data, the P1 Lys 
residue at the reactive site made the greatest contribution to the binding free energy for the complex 
formation. Whereas the contribution of the Thr residue at this position was reduced by almost half, but 
still quite substantial for both InhVJ and for the mutant BPTI Lys14Thr (Table 3).  
Table 3. The amino acid residues’ contribution to binding free energies and interfaces for 
the complexes of inhibitors with trypsin. Amino acid residues making the greatest 
contribution to binding free energy are highlighted in light green. 
 Reactive site Weak contact site 
BPTI (3OTJ) Pro12 Cys13 Lys14 Ala15 Arg16 Cys37 Arg38 Lys45 
ΔGbind, Kcal/Mol −2.1 −4.8 −8.1 −3.3 −3.2 −1.8 −2 1.1 
ΔSASA, Ǻ2 33 51.6 165.2 36 110.8 27.2 97.2 0 
BPTI mutant (3BTT) Pro12 Cys13 Thr14 Ala15 Arg16 Cys37 Arg38 Lys45 
ΔGbind, Kcal/Mol −2.1 −4,6 −4.4 −3.5 −3.5 −1.7 −1.6 0.3 
ΔSASA, Ǻ2 37.9 55.5 101.4 36.5 118.3 28.6 94.6 0 
SHPI-1 (3M7Q) Arg12 Cys13 Lys14 Gly15 Tyr16 Cys37 Gly38 Glu45 
ΔGbind, Kcal/Mol −3.4 −2.9 −8.4 −2.2 −4.5 −1.4 −0.1 −0.5 
ΔSASA, Ǻ2 143.8 52 163.6 19.9 88.7 30 0.9 0 
InhVJ Pro12 Cys13 Thr14 Ala15 Tyr16 Cys37 Glu38 Glu45 
ΔGbind, Kcal/Mol −2.1 −4.4 −4.7 −2.6 −5.9 −1.1 −0.2 −8.4 
ΔSASA, Ǻ2 50.5 53 106.1 30.5 102.2 37.2 0 37.9 
It should be noted that the presence of Tyr16 in InhVJ instead of Arg16 in BPTI was more 
advantageous in terms of solvation energy. One can see the decrease of the binding free energy from  
−3.2 Kcal/Mol for the BPTI-trypsin complex to −5.9 Kcal/Mol for the InhVJ-trypsin complex. 
However, this advantage was not enough to compensate the energy loss caused by the Lys to Thr 
replacement. In this case there was the electrostatic potential weakening in the area of the InhVJ 
reactive site, which apparently resulted in the decrease of the Ki value of the InhVJ-trypsin complex.  
At the weak contact site of inhibitors, two residues make the main energy gain. BPTI Arg38 forms 
two hydrogen bonds with the Asn97 of trypsin (supplementary data), and contributes to the binding 
free energy by about −2.0 Kcal/Mol. At this position in the InhVJ molecule there occurs a negative 
charge (Glu38), which does not influence the complex binding free energy. At the same time, in the 
InhVJ-trypsin complex, Glu45 makes the most substantial negative contribution to the complex 
formation energy (−8.4 Kcal/Mol), unlike BPTI Lys45 with a positive contribution. The strong 
electrostatic attraction of Glu45 to Lys60 (Figure 8) of the enzyme summing up with the hydrogen 
bond formation with Lys60 as well as with Tyr39 (Supplementary data) apparently determines the 
orientation and additional stabilization of InhVJ in the complex. These facts indicate the enhancement 
of the weak contact site role, in particular the Glu45 residue, in the formation of a InhVJ-trypsin 
complex, while the role of the reactive site residues, in particular Thr14 and Tyr16, in our opinion might 
be the stabilization of the complex through the formation of hydrophobic interactions and hydrogen 
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bonding networks. According to computational data, a similar regularity of the role of enhanced weak 
contact site residues was observed for the InhVJ-α-chymotrypsin complex (data is not shown). 
Figure 8. «Anchor» residues with maximum binding free energies contribution upon 
formation complexes of InhVJ (a) and SHPI-1 (b) with trypsin. Trypsin is shown as a 
solvent accessible surface colored by atomic partial charges (red is negative, blue is 
positive). Inhibitors «anchor» residues represented as sticks. 
(a) (b) 
3. Experimental Section  
3.1. Purification of InhVJ 
Specimens of the sea anemone H. crispa (R. macrodactylus) were collected in the coral reefs of  
the Seychelles during a marine expedition aboard the research vessel “Academik Oparin”.  
Dr. C. D. Grybelniy (Zoological Institute of the Russian Academy of Sciences, Saint-Petersburg, 
Russia) confirmed the identity of the species. InhVJ was isolated from 70%-ethanol extract of  
H. crispa by the scheme, which included a hydrophobic chromatography on Polychrome-1, gel filtration 
chromatography on Bio-gel P-4 and ion-exchange chromatography on SP-Sephadex G-25 [19]. The 
obtained fractions were purified by RP-HPLC on Nucleosil C18 column (4.6 × 250 mm; Sigma 
Aldrich, USA) with monitoring at 214 nm. Solvent A was 0.1% trifluoroacetic acid (TFA) in water, 
solvent B was 0.1% TFA in acetonitrile. A linear gradient from 10% to 60% of solvent B concentration 
was performed at a flow rate of 0.5 mL/min for 60 min. As the result of the second purification by  
RP-HPLC under the same conditions the individual polypeptide was obtained. 
3.2. Chemical and Enzymatic Treatment 
InhVJ was reduced and alkylated with 4-vinylpyridine as described in [19]. The resulting product 
was purified by RP-HPLC on a Nucleosil C18 column (4.6 × 250 mm; Sigma Aldrich, USA) with 
monitoring at 214 nm. Solvent A was 0.1% TFA in water, solvent B was 0.1% TFA in acetonitrile. A 
linear gradient from 10 to 60% of solvent B concentration was performed at a flow rate of 0.5 mL/min 
for 100 min. Alkylated polypeptide was digested with trypsin (Sigma Aldrich, USA) 1:50 (w/w) in  
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300 µL of 100 mМ ammonium bicarbonate (рН 8.0) at 37 °С for 24 h. Tryptic peptides were separated 
and desalted by RP-HPLC.  
3.3. Physical-Chemical Characterization 
Molecular weight determination of InhVJ and tryptic peptides was performed by matrix-assisted 
laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS) in linear positive ion 
mode, using BIFLEX-III instrument (Bruker Daltonic, Germany). Sinapinic acid was used as a matrix. 
Angiotensin-II (Sigma, USA) and matrix peaks were used for calibration of the instrument. The  
amino acid sequences of tryptic peptides were determined on an automated sequencer protein  
«Procise 492 cLC» (Applied Biosystems, USA). 
3.4. RACE Techniques, Cloning Experiments and Sequencing 
The full-length cDNA of InhVJ was performed by 3′ and 5′RACE technique with H. crispa 
tentacles cDNA synthesized previously [57]. The nucleotide sequences of the primers and PCR 
conditions were the same as described in [30]. Briefly, the first 3′RACE reaction was performed with a 
degenerate Inh 1 primer and the second 3′RACE one did with a degenerate Inh 2 primer. On the basis 
of the determined partial 3′RACE sequences, the remaining 5′-terminal sequences were obtained using 
three gene-specific primers: RmIn-1-5 (step 1), RmIn-AVJ (step 2), and RmIn-3-5AVJ (step 3). 
The 3′RACE (~300 bp) and the 5′RACE (~200 bp) PCR fragments were gel separated, purified and 
TA cloned (Fermentas, UAB) into Escherichia coli Top10 strain (Invitrogen, USA). Plasmids were 
sequenced by the dideoxy chain termination method using the ABI PRISM 3130xL Genetic Analyzer 
(Applied Biosystems, USA). cDNA sequences were analyzed applying the CromasPro (Applied 
Biosystems, USA) and Vector NTI (Invitrogen, USA) programs.  
3.5. Phylogenetic Analysis 
Searching homology sequences analysis was carried out using protein databases and BLAST 
programs [32]. Phylogenetic analysis of the known sea anemone Kunitz-type protease inhibitors  
was performed using the neighbor-joining (NJ) method with Poisson correction [58,59] in the  
MEGA 4 [37]. The bootstrap was performed with 1000 replicates. BPTI was used as an out-group.  
3.6. Expression of Voltage-Gated Ion Channels in Xenopus Laevis Oocytes 
For the expression of voltage-gated potassium channels (rKV1.1, rKV1.2, hKV1.3, rKV1.4, rKV1.5, 
rKV1.6, Shaker IR, rKV2.1, hKV3.1, rKV4.2, rKV4.3, hERG), and the capsaicine receptor (TRPV1)  
in Xenopus laevis oocytes, the linearized plasmids were transcribed using the T7 or SP6  
mMESSAGE-mMACHINE transcription kit (Ambion, USA). The harvesting of stage V-VI oocytes 
from anaesthetized female X. laevis frogs was previously described [60]. Oocytes were injected with 
50 nL of cRNA at a concentration of 1 ng/nL using a micro-injector (Drummond Scientific, USA). The 
oocytes were incubated in a solution containing (in mM): NaCl, 96; KCl, 2; CaCl2, 1.8; MgCl2, 2 and 
HEPES, 5 (pH 7.4), supplemented with 50 mg/L gentamycin sulfate. 
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3.7. Electrophysiological Recordings 
Two-electrode voltage-clamp recordings were performed at room temperature (18–22 °C) using a 
Geneclamp 500 amplifier (Molecular Devices, USA) controlled by a pClamp data acquisition system 
(Axon Instruments, USA). Whole cell currents from oocytes were recorded 1–4 days after injection. 
The bath solution composition was ND96 (in mM): NaCl, 96; KCl, 2; CaCl2, 1.8; MgCl2, 2 and 
HEPES, 5 (pH 7.4) or HK (in mM): NaCl, 2; KCl, 96; CaCl2, 1.8; MgCl2, 2 and HEPES, 5 (pH 7.4). 
Voltage and current electrodes were filled with 3 M KCl. Resistances of both electrodes were kept 
between 0.5 and 1.5 MΩ. The elicited currents were filtered and sampled at resp. 1 kHz and 10 kHz 
(for potassium currents) and at resp. 0.2 kHz and 0.5 kHz (for TRPV1 currents), using a four-pole  
low-pass Bessel filter. Leak subtraction was performed using a P/4 protocol. KV1.1-KV1.6 and Shaker 
currents were evoked by 500 ms depolarizations to 0 mV followed by a 500 ms pulse to −50 mV, from 
a holding potential of −90 mV. Current traces of hERG channels were elicited by applying a +40 mV 
prepulse for 2 s followed by a step to −120 mV for 2 s. KV2.1, KV3.1 and KV4.2, KV4.3 currents were 
elicited by 500 ms pulses to +20 mV from a holding potential of −90 mV. TRPV1 currents were 
measured in ND96 solution using a protocol of −90 mV during 400 s. The recording chamber was 
perfused at a rate of 2 mL min−1 with a ND-96 solution containing (in mM) 96 NaCl, 2 KCl,  
1.8 CaCl2, 1 MgCl2, 5 HEPES, pH 7.4. As previously described [61], capsaicin (2 μM) was used as an 
agonist and capsazepine (10 μM) as an antagonist of TRPV1. Capsaicin and capsazepine were 
purchased from Sigma. All data represent at least three independent experiments (n ≥ 3) and are 
presented as mean ± standard error.  
3.8. Homology Modeling and Docking 
A InhVJ spatial structure model was generated by homology modeling method using  
SWISS-MODEL server [49] with the Kunitz type sea anemone polypeptide SHPI-1 crystal structure 
(PDB ID 1SHP) as a template [47]. Generated models were energy minimized using the MOE 
software with the capacity of the OPLS-AA [51]. Stereochemical quality was checked using 
Ramachandran plot and PROCHECK server [52,53].  
The structural models of the InhVJ-trypsin as well as InhVJ-α-chymotrypsin complexes were 
generated using the molecular docking method by the ClusPro2.0 server resources [62]. Crystal structure 
of trypsin and α-chymotrypsin were extracted from 2PTC [63] and 1CBW [64] PDB files, respectively. 
Analysis of molecular interface and amino acid residue contribution to complex stabilization were 
performed using webservers ANCHOR [65,66] and PDBe PISA [67]. “Anchor” residues was 
identified as five amino acid residues of those that showed the maximum contribution to the predicted 
binding free energy and change in solvent accessible surface area (ΔSASA) for enzyme-inhibitor 
complexes [68]. Visualizations were performed using DS Visualizer 2.5 Accelrys® software. 
4. Conclusions  
Sea anemones are known to produce a large amount of Kunitz-type polypeptides, which can possess 
the feature of a protease inhibitor as well as of a modulator of Kv or TRPV1 channels. InhVJ, a new 
Kunitz-type inhibitor with the so-called P1 Thr residue is specific to trypsin-like proteases and does 
Mar. Drugs 2012, 10 1561 
 
 
not modulate Kv or TRPV1 channels. This inhibitor forms a stable complex with trypsin and is 
stabilized by H-bonds of the P1 Thr residue at the reactive site with the protease active site residues, as 
well as via electrostatic interaction and H-bonds of Glu45 at the weak contact site with protease Lys60 
and Tyr39. 
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